With the SOUL trial, oral semaglutide becomes the worlds first and only oral GLP-1 RA with proven CV benefits
Medicaid coverage for GLP-1 medications varies significantly across states, with some plans covering them for weight management and others limiting access to diabetes treatment only
Ma H, Huang W, Wang X et al (2020) Structural insights into the activation of GLP-1R by a small molecule agonist
Habits become more sustainable, and motivation tends to grow
In pancreatic -cell research models this cascade is associated with glucose-dependent insulin secretion, suppression of glucagon release, and protection against lipotoxic apoptosis
Many clients notice a boost in energy and mood within 2448 hours after their injection, while others experience more gradual improvements over several days